GeoVax Labs, Inc. Warrants - GOVXW STOCK NEWS

Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.

GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.

Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.

Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.

Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.

07/26/2023 09:00 AM

News

GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

11.62%

Tags

07/24/2023 09:00 AM

News

GeoVax Announces Issuance of Ebola Vaccine Patent

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.96%

Tags

07/20/2023 09:00 AM

News

GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Rhea-AI Summary

GeoVax Labs has announced the start of a clinical trial for its GEO-CM04S1 COVID-19 vaccine in patients with chronic lymphocytic leukemia. The trial will compare the immune response of GEO-CM04S1 to the Pfizer-BioNTech vaccine as a booster in these vulnerable patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.18%

Tags

07/10/2023 09:00 AM

News

GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference

Rhea-AI Summary

GeoVax Labs presents Phase 1/2 clinical trial data for gene therapy candidate Gedeptin at AACR and AHNS conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.47%

Tags

06/28/2023 09:00 AM

News

GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference

Rhea-AI Summary

GeoVax Labs, Inc. announces that its gene therapy candidate, Gedeptin®, will be presented at the American Association for Cancer Research and American Head and Neck Society joint conference. The abstract focuses on a Phase 1/2 study of Ad/PNP with fludarabine for the treatment of head neck squamous cell carcinoma (HNSCC).

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.73%

Tags

06/27/2023 10:15 AM

News

GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights

Rhea-AI Summary

GeoVax Labs, Inc. announces the publication of an article on the development of a next-generation COVID-19 vaccine. The vaccine, GEO-CM04S1, is designed to induce both antibody and T cell responses to non-variable parts of the virus, providing protection against emerging variants. Initial data shows promising immune responses in patients with reduced immune system function. The vaccine is currently being tested in Phase 2 clinical trials.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.96%

Tags

05/31/2023 09:00 AM

News

GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.47%

Tags

05/25/2023 09:00 AM

News

GeoVax to Participate in Upcoming Industry Meetings

Rhea-AI Summary

GeoVax Labs, Inc. announced that its Chief Medical Officer will participate in the ASCO Annual Meeting and its Chairman and CEO, along with other senior management, will participate in the BIO International Convention.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.67%

Tags

05/24/2023 08:00 AM

News

GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients

Rhea-AI Summary

GeoVax Labs presents updates on its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including positive preliminary data from an ongoing Phase 2 clinical trial. The vaccine shows high immunogenicity in patients undergoing hematological cancer treatment, supporting its progression in the study.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

14.16%

Tags

05/15/2023 09:00 AM

News

GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.08%

Tags

FAQ

What is the current stock price of GeoVax Labs Warrants (GOVXW)?

The current stock price of GeoVax Labs Warrants (GOVXW) is $0.1209 as of November 22, 2024.

What is GeoVax Labs, Inc. focused on developing?

GeoVax Labs, Inc. is focused on developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers using innovative proprietary platforms.

What recent achievements has GeoVax Labs, Inc. made?

GeoVax Labs, Inc. achieved positive initial safety and immune response findings in a Phase 2 clinical trial for its COVID-19 vaccine.

Which diseases are targeted by GeoVax's vaccine development programs?

GeoVax targets infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), Zika virus, along with developing immunotherapies for various solid tumors.